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Summary
Natural products of microbial origin are widely used
as pharmaceuticals and in agrochemistry. These com-
pounds are often biosynthesized by multifunctional
megasynthetases whose genetic engineering and
heterologous expression offer considerable promise,
especially if the natural hosts are genetically difficult
to handle, slow growing, unculturable, or even un-
known. We describe a straightforward strategy that
combines the power of advanced DNA engineering
(recombiogenic cloning) in Escherichia coli with the
utility of pseudomonads as the heterologous host for
the analysis and mutagenesis of known and unknown
secondary metabolite pathways. The myxochromide
S biosynthetic gene cluster from Stigmatella auranti-
aca was rebuilt and engineered in E. coli to contain
the elements required for expression in pseudomo-
nads. The successful production in Pseudomonas
putida, at unprecedented levels, demonstrates the
feasibility of the new approach to the analysis and
mutagenesis of these important pathways.
Introduction
Myxobacteria are a rich source of natural products with
biological activity. So far, about 100 different core struc-
tures and 500 variants have been characterized [1].
Many of these compounds illustrate that myxobacteria
specialize in rare mechanisms of action. For example,
20 new electron transport inhibitors and 10 substances
that act on the cytoskeleton have been found [1]. Most
myxobacterial substances are moderately lipophilic,
linear or cyclic polyketides and peptides synthesized
by large multifunctional enzymes known as polyketide
synthases (PKSs) and nonribosomal peptide synthe-
tases (NRPSs) [2–5]. These enzymes are organized in a*Correspondence: rom@mx.uni-saarland.demodular fashion and catalyze the successive conden-
sation of acyl-CoA (PKS) or activated amino acid build-
ing blocks (NRPS). Usually, each module is responsible
for one discrete chain elongation step and can be sub-
divided into domains controlling not only the choice of
the extender unit but also the further modification of
the growing chain. These modular enzyme systems
present the possibility that the specificity or sequence
of reactions can be manipulated by DNA engineering to
produce novel therapeutic compounds [6, 7].
Over the past decade, numerous PKS and NRPS bio-
synthetic gene clusters have been cloned including
several from myxobacterial producers, notably the
electron transport inhibitors myxothiazol and melithia-
zol [8, 9] and the potential anticancer agents, epothi-
lones and tubulysins [10–12]. Increasing biochemical
knowledge from studies dealing with the corresponding
enzymes has led to the emergence of combinatorial
biosynthesis technologies aimed at generating novel
compounds through genetic manipulation [6, 7]. In con-
trast to numerous intensively studied streptomycetes,
genetic systems for the modification of the slow grow-
ing myxobacterial producers have proven difficult. Nev-
ertheless, expression of the epothilone biosynthetic
gene cluster in streptomycetes [13] and in Myxococcus
xanthus [14] has been achieved. The methodology em-
ployed relied on several rounds of cloning and heterolo-
gous host modification, which was tedious and time
consuming. In addition, the yields were worse than in
the natural producer, Sorangium cellulosum [15].
We now report the genetic engineering and heterolo-
gous expression of the first myxobacterial gene cluster
in pseudomonads, which were found to present excel-
lent host properties (for the general procedure of the
approach see Figure 1). To facilitate the ease of
transfer, the entire cluster was rebuilt on one molecule,
and the DNA elements for transfer, stable maintenance,
and inducible expression were introduced using homol-
ogous recombination in E. coli [16–18], also termed re-
combineering or recombiogenic cloning [19].
The gene cluster used here encodes a PKS/NRPS hy-
brid that directs the biosynthesis of different forms of
myxochromide S, which are cyclic peptides with unsat-
urated polyketide side chains (Figures 2 and 4A) [20].
These compounds are produced by the myxobacterium
Stigmatella aurantiaca in yields up to 8 mg/l. The gene
cluster exhibits several interesting biosynthetic fea-
tures (Figure 2). The NRPS part of the gene cluster con-
tains six NRPS modules, although only five amino acids
are incorporated into the molecule. By comparison of
the deduced substrate specificities of the adenylation
domains, it was proposed that module four is skipped
during the biosynthetic process [20]. In addition, the
gene cluster harbors only one type I PKS module that
was assumed to form the complete polyketide side
chain and therefore believed to act iteratively. The suc-
cessful expression of the complete myxochromide S
biosynthetic gene cluster in the heterologous host
P. putida now provides direct evidence for the iterative
use of the type I bacterial PKS.
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350Figure 1. General Strategy for the Cloning and Heterologous Expression of Large Natural Product Assembly Lines
After screening of the library for constructs containing parts of the investigated natural product biosynthetic gene cluster, overlapping frag-
ments can be stitched together in E. coli using Red/ET recombineering. The resulting construct harboring the complete natural product
assembly line can be further modified in E. coli by recombineering, e.g., inserting genes needed for transformation in the heterologous host
and/or insertion of promoter region(s). The final construct can be transferred into a suitable heterologous host for expression of the biosyn-
thetic pathway. Natural product formation can finally be analyzed by conventional techniques, e.g., HPLC and/or TLC.The applied strategy of combining the power of ad- p
Svanced DNA engineering and mutagenesis in Escher-
michia coli with the utility of pseudomonads as the heter-
oologous host provides a new avenue for the analysis
tand mutagenesis of known and unknown (not only
pmyxobacterial) secondary metabolite pathways in the
mfuture (see Figure 1).
t
t
Results P
i
Construction of the Complete Myxochromides S N
Gene Cluster on a Transferable Cosmid s
The myxochromide S biosynthetic gene cluster has A
been cloned and sequenced previously [20]. The origi- w
nal cosmid E196 does not contain the full-length path- r
way because it is missing the thioesterase (TE) domain r
of the second NRPS. To complete the myxochromide S w
biosynthetic gene cluster and add the necessary ele- s
ments for conjugation, integration, and expression in d
pseudomonads, the original cosmid E196 was modified n
sequentially by recombineering using the Red/ET re- 3
combination [16–18]. In brief, the backbone of cosmid g
E196 was modified by single-step insertion of the origin a
of transfer (oriT) for conjugation purposes, the tetracy- o
cline-resistance gene for selection in P. putida, and a
DNA fragment from the chromosome of P. putida (trpE) T
to enable the integration of the construct into the ge- C
nome by homologous recombination, to create the T
mSuperCos derivative CMch34 (Figure 3A). During thisrocedure, the original ampicillin-resistance gene of
uperCos was deleted. To reconstruct the complete
yxochromide S pathway on CMch34, the missing part
f the TE domain had to be added. The sequence of
he full-length TE domain was available on pMch2, a
reviously described recovery plasmid from a NRPS
utant strain [20] (see Figure 2). To stitch the missing
hioesterase piece of the gene cluster onto CMch34,
he zeocin-resistance gene (zeoR) was amplified by
CR reaction and inserted into pMch2 by recombineer-
ng, resulting in plasmid pMch23. Then, a 3.5 kb StuI/
deI fragment from pMch23 containing the TE-zeoR cas-
ette was recombined with CMch34 to create CMch36.
s a final step, the toluic acid inducible Pm promoter
as inserted in front of the first gene of the myxoch-
omide S cluster. Together with the chloramphenicol-
esistance gene and the xylS gene, the Pm promoter
as inserted into CMch36 to create CMch37. This in-
ertion was designed to not only place the promoter
irectly in front of the PKS but also to delete five genes
ot involved in myxochromide S biosynthesis (Figure
A). The final construct CMch37 contains only the three
enes from the myxochromides S pathway (one PKS
nd two NRPSs), with the Pm promoter placed in front
f the PKS.
ransfer of the Myxochromides S Biosynthetic Gene
luster into Pseudomonads
he final construct CMch37, containing the complete
yxochromide S biosynthetic gene cluster, was trans-
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351Figure 2. Gene Arrangement and Domain Organization of the mch Biosynthetic Gene Cluster from S. aurantiaca DW4/3-1 and a Model for
the Biosynthesis of Myxochromide S
The inserts of cosmid E196 and additional sequences derived from plasmid pMch2 are indicated by lines. Genes are shown as arrows, which
also indicate the direction of transcription. mchA encodes a PKS, while mchB and mchC encode NRPSs. For description of the flanking
regions, see [20]. PKS domains are shown in green, and NRPS domains are shown in red. The methyltransferase (MT) domain is shown in
yellow, while the thioesterase (TE) domain is marked in blue. Gray domains are presumably inactive. Transfer of the peptide chain from the T
(thiolation) domain of module 3 to the T domain of module 5 is indicated. A, adenylation domain; C, condensation domain; KS, β-ketosynthase
domain; AT, acyltransferase domain; DH, dehydratase domain; ER, enoylreductase domain; KR, ketoreductase domain; ACP, acyl carrier
protein domain. (Modifed from [20].)ferred into Pseudomonas putida by triparental conjuga-
tion as previously described [21]. Conjugants were
screened on PMM agar containing tetracycline for the
selection of P. putida::CMch37 mutants. The donor strain
was additionally counterselected by ampicillin, which P.
putida is resistant to. Thousands of exconjugants were
obtained per conjugation. Ten randomly chosen colo-
nies were analyzed by PCR, which verified the inte-
gration of CMch37 into the P. putida chromosome in
each case.
Production of Myxochromide S in Pseudomonads
To induce expression from the Pm promoter, toluic acid
was added to cultures after 2 hr of fermentation. Com-
pared to 30°C, cultivation at 16°C after the induction
resulted in a more than 1000-fold increase of myxo-
chromide S production, reaching a maximum yield of
approximately 40 mg/l. This is about five times greater
than the maximum found with the natural producing
host S. aurantiaca. Furthermore, new myxochromide S
derivatives could be identified in these extracts by
HPLC/MS analysis (Figure 4). In addition to myxochrom-
ides S1-3 known from S. aurantiaca (which were iden-
tified by comparison to authentic reference standards),the MS data from extracts indicate the presence of
the corresponding compounds lacking the threonine
N-methyl group and thus representing new myxochrom-
ide S derivatives.
Myxochromides were only detected in the cells and
not in the fermentation medium, indicating that P. pu-
tida is not able to export these secondary metabolites
out of the cell. A kinetic analysis (data not shown) of
myxochromide S production in P. putida::CMch37
mutants reveals that the production maximum was
reached after 2–3 days, which surpasses the 6 days re-
quired for S. aurantiaca to reach maximum production.
Discussion
Heterologous expression of complete secondary me-
tabolite pathways is of increasing interest in natural
product research and drug discovery. It is a viable alter-
native to both strain and fermentation process develop-
ment and molecular biological manipulation of the na-
tive producer strain [22]. Several strategies for the
heterologous expression of secondary metabolite path-
ways have been described in the literature so far, rang-
ing from the targeted expression of specific natural pro-
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352Figure 3. Description of the Cloning Procedure
(A) Maps of cosmid E196 and the Red/ET recombination contructs cosmid CMch34, CMch36, and CMch37 with virtual PvuII restriction,
indicated by dotted lines.
(B) Restriction analysis of cosmid E196 and the Red/ET recombination contructs cosmid CMch34, CMch36, and CMch37 with the indicated
restriction enzymes including PvuII.ducts to the expression of large unknown DNA t
tfragments. In the later approach, bacterial artificial
chromosome (BAC) shuttle vectors were used for con- c
lstructing environmental libraries followed by expres-
sion in multiple expression hosts (pseudomonads, t
streptomycetes, and E. coli) [23, 24]. However, only pro-
ducts from relatively small biosynthetic gene clusters p
chave been produced with this method so far, and the
producing heterologous host has always been from the s
gsame genus as the natural producer [23].
For gene transfer into streptomycetes, an elegant b
hmethod based on the RecA methodology for the as-
sembly of large DNA pieces in E. coli-streptomyces ar- f
dtificial chromosomes has been developed [25, 26]. As
observed by these authors, cosmid instabilities in the h
spresence of RecA recommend the use of inducible sys-ems, such as used here for regulated expression of
he Red proteins. Although more experience with larger
omplexes is required, we note that undesired DNA de-
etions and rearrangements were only rarely observed
hroughout our recombineering.
There are a number of reports on the heterologous
roduction of biosynthetic pathways from streptomy-
etes in related actinomycetes. Here, mostly relatively
mall type II PKS systems were used [27–32]. Heterolo-
ous expression of large PKS and/or NRPS genes has
een achieved by coexpression from several plasmids
arboring parts of the biosynthetic pathway [33]. The
easibility of the production of complex natural pro-
ucts (exemplified by the aglycon of erythromycin) after
eterologous expression in unrelated bacteria has been
hown in a genetically engineered E. coli host [22].
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353Figure 4. Myxochromide Production in Pseudomonads
(A) Structures of myxochromides S1–S3 (1–3) produced by the myx-
obacterium S. aurantiaca DW4/3-1.
(B) HPLC profiles from extracts of the P. putida/CMch37 mutant
strain in comparison to P. putida wild-type and the natural myxo-
chromide S producer S. aurantiaca DW4/3-1 (diode array detection
at 200–400 nm). Numbers correspond to substances as follows:
1–3, see (A); 4 and 5 are assumed to be the corresponding Des-
N-methylderivatives from 1 and 3 (see main text). Some additional
novel peaks of currently unknown structure and presumably unre-
lated to myxochromides occur in P. putida/CMch37. M. myxothia-
zol; mAU, mili absorption units.Similarly, both epothilone and soraphen derived from
the myxobacterium S. cellulosum have been produced
in streptomycetes [13, 34], and a multistep procedure
enabled epothilone production in M. xanthus [35]. One
could argue that a large BAC library would always en-
able the cloning of complete biosynthetic gene clusters
on one DNA molecule. Nevertheless, this has never
been described for a heterologous expression, which is
presumably due to the fact that most of the BACs from
a library statistically only carry fragments of each gene
cluster. In fact, we have not been able to identify a BAC
harboring a complete 90 kbp PKS pathway in a library
of S. cellulosum covering 15 genome equivalents
(average insert size ranging from 80 to 180 kbp; O. Per-
lova and R.M., unpublished data). In addition, it is still
a difficult task to prepare BACs of sufficient insert size.
Despite increasing experience with heterologous
hosts, typically the levels of production have been
much lower than those in the original producer. This
may be due to weakness of the natural promoter in the
heterologous host. Futhermore, in all of the studies
mentioned above, classical and time-consuming clon-
ing procedures were employed, and the expression of
large secondary metabolite clusters was only achieved
by coexpression from several plasmids. In this study,
we describe the application of recombinogenic engi-
neering in E. coli for cloning of a large natural product
assembly line. This straightforward technique is partic-
ularly suitable for large DNA molecules such as BACs
and cosmids and is therefore ideal for engineering of
PKS and NRPS pathways. We used this method to re-
build the complete assembly line from a myxobacterial
PKS/NRPS hybrid gene cluster in one cosmid (final size
after deletion of genes not required for myxochromid
biosynthesis: 43 kbp) and to introduce the elements re-
quired for conjugation, stable integration, and regu-
lated expression. The most important advantage of this
method is that the whole secondary metabolite path-
way is located on one construct, which can be transfer-
red into the heterologous host strain (see Figure 1). As
recombineering is based on homologous recombina-
tion, one might have expected difficulties using the de-
scribed method in the assembly of repetitive sequences.
Nevertheless, in related projects employing gene clus-
ters up to 80 kbp in size, we have already demonstrated
that even highly repetitive sequences can be recom-
bined. The introduction of several promoters into one
pathway can be facilitated by employing counterse-
lectable markers to delete and then reuse the marker
genes employed (S.C.W., F.G., Y.Z., A.F.S., and R.M.,
unpublished data).
To transfer the complete pathway into pseudomo-
nads in one step, the origin of transfer (oriT) for conju-
gation, the tetracycline-resistance gene as selection
marker, as well a homologous region (trpE) for integ-
ration into the pseudomonads genome were inserted
into the construct. The trpE gene was used for homolo-
gous integration into the P. putida genome because it
is not essential for growth on rich media. The original
myxobacterial promoter had also to be changed
against a regulatory element working in the heterolo-
gous host strain pseudomonads (Pm promoter). We
chose the toluic-acid-inducible Pm promoter [36, 37] in
order to control the myxochromide S expression. The
Chemistry & Biology
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secondary metabolite product of the pathway could be b
toxic for the host strain. An inducible promoter allows E
for the control of secondary metabolite expression and s
thus permits the establishment of the pathway in the c
host regardless of toxicity. Notably, in the case of an m
unknown pathway, toxicity after expression will be an c
interesting first sign that the molecule is antibiotically w
active. e
After conjugation of the final construct (CMch37) into h
the heterologous host strain P. putida, the myxochrom- d
ide S biosynthetic gene cluster was integrated into the w
chromosome with high efficiency. All of the recombi- g
nants tested were verified as genotypically correct. The m
resulting P. putida mutant strain (P. putida/CMch37) r
was shown to overproduce myxochromide S approxi- i
mately 5-fold in comparison to S. aurantiaca, unambig- p
uously proving that the inserted fragment carries all a
genes necessary for the biosynthesis. e
These data clearly show that only one PKS module l
is responsible for the formation of the complete polyke- P
tide side chain, which is direct evidence for an itera- a
tively working myxobacterial type I polyketide syn- i
thase. As for other iterative PKSs, the determination of d
the polyketide chain length remains a mystery. The m
functional heterologous expression of the myxochrom- [
ide pathway now sets the stage for a detailed analysis N
by mutagenesis of MchA. In addition to the already h
characterized products from the natural producer d
S. aurantiaca (myxochromides S1-3), new myxochrom- t
ide S derivatives could be detected in the extracts of s
the heterologous host by HPLC/MS analysis. The MS a
data indicate that these compounds correspond to t
myxochromides S1 and S3 lacking the threonine l
N-methyl group. Possibly, S-adenosyl-methionine m
(SAM)-dependent methylation in P. putida catalyzed by p
the N-methyltransferase domain of the first NRPS m
MchB did not proceed efficiently because SAM may t
become limiting once production reaches a certain p
limit. Alternatively, these new minor myxochromide S p
derivatives may be detectable because of the high yield i
of myxochromide S produced by the heterologous s
host. These questions also highlight the need to under- C
stand the underlying natural product formation in more
a
detail to enable efficient combinatorial biosynthesis.
a
Due to the flexibility of our approach, these studies are
inow straightforward. For example, elucidation of the
tunique module skipping process is underway.
dOnly two myxobacterial products (epothilone and sora-
ephen) have been expressed in a heterologous host so far,
band their production yields in streptomycetes were poor
(<0.5 mg/l) [13, 34]. Additionally, epothilone production in
Sthe myxobacterium M. xanthus has been described [14],
but this organism is very difficult to handle in fermentation
Tprocesses [15]. Thus, efficient heterologous expression
nof biosynthetic gene clusters from microbial producers
cother than actinomycetes is still a challenging task, es-
ppecially for the slow-growing myxobacteria or cyano-
hbacteria. The work presented here demonstrates that
fP. putida provides an important alternative host for the
wproduction of myxobacterial secondary metabolites.
oWe chose pseudomonads as the heterologous host for
nseveral reasons. First, pseudomonads are genetically
well established and grow rapidly, and Pseudomonas gutida KT2440 is available as a “safety strain” that has
een completely sequenced [38]. Pseudomonads and
. coli conjugate efficiently, and as opposed to most
econdary-metabolite-producing hosts, pseudomonads
an be readily transformed with DNA using physical
ethods. Additionally, several E. coli elements, such as
ertain promoters and certain plasmid replication origins,
ork in pseudomonads, in contrast to the paucity of such
lements in the major secondary-metabolite-producing
osts. Furthermore, pseudomonads have excellent en-
ogenous properties for homologous recombination,
hich enables efficient integration into the endogenous
enome for stable maintenance of introduced DNA
olecules. Pseudomonads provide further advantages
egarding the expression and activation of myxobacter-
al secondary metabolite gene clusters. For examples,
seudomonads have a high GC genomic content and
codon preference that is more suitable than E. coli for
xpression of genes from the major secondary metabo-
ite producers, the actinomycetes and myxobacteria.
. putida also harbors a phosphopantetheinyl transfer-
se (P-pant transferase) with broad substrate specific-
ty, which is able to activate both the acyl carrier protein
omains (ACPs) and the peptidyl carrier protein do-
ains (PCPs) from myxobacteria and streptomycetes
39]. The posttranslational modification of PKS and
RPS systems by attaching the P-pant moiety to a
ighly conserved serine residue of their ACP and PCP
omains (apo-holo-conversion) catalyzed by the P-pant
ranferases is essential for the activity of these mega-
ynthases [40]. In accordance with our data, Marahiel
nd coworkers have recently shown that the P-pant
ransferase from P. aeruginosa in vitro shows relatively
ow substrate specificity [41]. Unlike most secondary-
etabolite-producing hosts such as streptomyces,
seudomonads grow easily and rapidly in culture. With
yxochromide S production in P. putida, the fermena-
ion time is reduced 3-fold (2 versus 6 days), while the
roduct yield is 5-fold higher (40 versus 8 mg/l) in com-
arison to the natural producer S. aurantiaca. P. putida
s obviously able to produce all the activated precur-
ors needed for myxochromide S biosynthesis (acetyl-
oA, malonyl-CoA, and propionyl-CoA) and, due to its
bility to grow on valine as sole carbon source, it might
lso be able to produce methylmalonyl-CoA [42], which
s important for the production of numerous polyke-
ides. The production of methylmalonyl-CoA in pseu-
omonads might alternatively be ensured by metabolic
ngineering of the intracellular CoA pool, which has
een described in E. coli [43].
ignificance
he engineering of a complete polyketide synthase/
onribosomal peptide synthetase biosynthetic gene
luster in E. coli and its heterologous expression in
seudomonads is a straightforward strategy that
olds promise for discovery and engineering of drugs
rom nature. This strategy provides not only a useful
ay to circumvent the slow growth and poor genetics
f myxobacterial producers but also a way to scruti-
ize gene clusters of unknown function, including
ene clusters discovered by genome-scale sequenc-
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355ing projects with little or no supporting information.
Our strategy also provides an important step forward
in the production of “unnatural natural products”
through accurate manipulation of secondary metabo-
lites using advanced DNA engineering and mutagene-
sis in E. coli.
Experimental Procedures
Cloning of the Myxochromide S Cluster
All methods were essentially the same as described previously [16,
18]. For Red/ET recombination, a 50 µl aliquot of Red/ET-compe-
tent (ET+) E. coli cells harboring the parent molecule was electro-
porated with 0.3 µg of a linear fragment (either PCR product or
fragment obtained from restriction). After electroporation, colonies
that grew under selection for the antibiotic resistance gene were
examined for the intended Red/ET recombination product by re-
striction analysis with a set of different enzymes.
All PCRs were carried out using HotStarTaq Polymerase (Qiagen)
according to the manufacturer’s protocol. For the amplification of
thew600 bp zeocin cassette, Q-Solution (Qiagen) was added (20%
final concentration), and pcDNA3.1-Zeo(+) was used as template
with oligonucleotides MchET1 and MchET2. The conditions using
an Eppendorf mastercycler were as follows: 15 min at 95°C to acti-
vate the polymerase, denaturation at 95°C (30 s), annealing at 62°C
(30 s) (for cycles 1–4) or at 72°C (for cycles 5–30), and extension
at 72°C (40 s); 30 cycles. The PCR product was purified with the
NucleoSpin Extract Kit (Macherey-Nagel). The PCR for the amplifi-
cation of the 2.6 kbp Pm-xylS-chloramphenicol cassette was car-
ried out using JB-655-Cm as template with oligonucleotide primers
MchET5 and MchET6. DMSO was added to a final concentration
of 3%, and 50% glycerol was added to a final concentration of 8%.
The conditions using the Eppendorf mastercycler were as follows:
15 min at 95°C denaturation 95°C (30 s), annealing at 53°C (30 s),
and extension at 72°C (150 s); 30 cycles. The PCR product was
directly used without purification.
Oligonucleotide sequences were as follows. Oligos used for gen-
eration of CMch34: left (MchET1), 5#-TGCTTAATCAGTGAGGCA
CCTATCTCAGCGATCTGTCTATTTCGTTCATCTCGAATAGGGCGA
ATTGGGCC-3#; right (MchET2), 5#-AGTGAGGGTTAATTGCGGCCG
CGAATTCTTGAAGACGAAAGGGCCTCGTGATATTACTTGGCGGAA
GTCTGCTC-3#. Oligos used for generation of pMch23: left (MchET3),
5-CATTCAAGCGCGCGCTGGGGAAGGCAGGCAGGATGGGATCTG
ATCAGCACGTGTTG-3#; right (MchET4), 5#-TGATAAGCGGTCAAAC
ATGAGAATTCGCGGCCGCATAATACGACTCACTATAGTCAGTCCTG
CTCCTCGGCCAC-3#. Oligos used for generation of CMch37: left
(MchET5), 5-TGAGCCCCGCGTCCCGCAGGGCCCGGGCGATGCAA
TACTCACTGGAGATTTAAATCCTGGTGTCCCTGTT-3#; right (MchET6),
5#-TGGACACTACCCCACGGCTAGAAACTTCGGTCAATACAGAATT
TCCTATCATGTTCATGACTCCATTATT-3#.
Conjugation into Pseudomonads
The SuperCos derivative CMch37 (size: 43 kbp) was transferred
into the pseudomonads strain P. putida KT2440 by conjugation.
The triparental mating was performed by combining 50 µl of a 300
µl suspension from 1 ml of overnight cultures of E. coli XL-1 Blue
containing CMch37, E. coli HB101 containing the helper plasmid
pRK2013, and P. putida on a small area of a Luria agar plate [21].
After incubation at 37°C for 4 hr, the plate was transferred to 28°C–
30°C and incubated overnight. The cells were scraped from the
plate, resuspended in sterile water, and plated out on PMM agar
amended with ampicillin (100 µg/ml) and tetracyclin (30 µg/ml). The
plates were incubated for 1–2 days at 28°C–30°C. Transconjugants
were screened by colony PCR using HotStarTaq Polymerase
(Qiagen) according to the manufacturer’s protocol. DMSO was
added to a final concentration of 3%, and 50% glycerol to a final
concentration of 8%. The oligonucleotides Mch35 (5#-CACGAG
CTCGTCCTGGATGCCGAGATTG-3#) and Mch36 (5#-GGCTCTAGA
AGCGTCCGGCCGTCATAC-3#) were used, yielding an about 700 bp
PCR product. The conditions using the Eppendorf mastercycler
were as follows: 15 min at 95°C for activation of the polymerase,denaturation for 30 s at 95°C, annealing for 30 s at 53°C, and exten-
sion for 40 s at 72°C; 30 cycles.
Expression and Analysis
The P. putida strain containing the myxochromide S biosynthetic
gene cluster (P. putida/CMch37) was incubated in 2 l flasks con-
taining 500 ml Luria broth amended with ampicillin (100 µg/ml) and
tetracycline (30 µg/ml). The culture was inoculated with an over-
night culture (1:100) and incubated for 1–2 hr at 30°C on a rotary
shaker. After induction with toluic acid (5 mM), the culture was
transferred to 16°C and incubated for 2–3 days. The cells were
harvested by centrifugation and extracted with acetone. The ex-
tract was evaporated and redissolved in 500 µl of methanol, and
10 l of the concentrated extract was analyzed by HPLC-MS (Ag-
ilent 1100 LC system). The chromatographic conditions were as
follows: column, ET 125 × 2 mm, and precolumn, Nucleosil 120-5-
C18; solvent, 5% acetonitrile, 95% water, 5 mM ammonium acetate,
0.003% acetic acid (A), and 95% acetonitrile 5% water, 5 mM am-
monium acetate, 0.003% acetic acid (B); solvent gradient from 10%
B at 0 min to 100% B within 30 min, followed by 10 min with 100%
B; flow rate, 0.3 ml/min. The detection was carried out at 400 nm,
and for mass detection a Perkin Elmer Sciex API 2000 mass spec-
trometer equipped with a TurbolonSpray source was used. Myx-
ochromides S1–3 were identified by comparison to the retention
times and the MS data of authentic standards (myxochromide S1:
Rt = 21.0 min, [M+H+] = 723; myxochromide S2: Rt = 22.0 min,
[M+H+] = 737; myxochromide S3: Rt = 22.8 min, [M+H+] = 749).
Quantitation of myxochromides was performed by comparison of
the peak areas in the HPLC chromatogram at 400 nm with the peak
areas in a calibration curve from the myxochromide S1 standard at
400 nm.
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